Abstract
This article focuses on the initial results achieved with the more selective immunosuppressive approach of B-lymphocyte depletion in patients who fail cyclophosphamide or have contraindications for its use in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This novel approach has sparked hope for patients and physicians in their search for effective, well-tolerated therapy for AAV. B-cell depletion is now undergoing rigorous investigation in randomized clinical trials.
Original language | English (US) |
---|---|
Pages (from-to) | 741-754 |
Number of pages | 14 |
Journal | Rheumatic Disease Clinics of North America |
Volume | 33 |
Issue number | 4 |
DOIs | |
State | Published - Nov 2007 |
ASJC Scopus subject areas
- Rheumatology